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Influence of perinatal nicotine administration on transplacental
carcinogenesis in Sprague Dawley rats by N-methylnitrosourea
M.R. Berger, E. Petru, M. Habs and D. Schmahl
In1stitute of Toxicology and Chemotherapy, German Cancer Research Center, Im Neuenheimer Feld 280, D-6900 Heidelberg,
FRG.
Summary The administration of nicotine during the perinatal stages of life resulted in a significant decrease
in tumours occurring after transplacental induction by N-methylnitrosourea (MNU). The overall tumour
incidence following p.o. application of MNU to dams was 85% in rats of the F,-generation, the main
occurrence being related to the neurogenic system (62% of the animals). Regular injections of nicotine before
or after birth resulted in a reduction of malignancies by 17% and 22% (P=0.08 and 0.0015), respectively.
The difference in the incidence of neurogenic tumours proved to be highly significant (P<0.002) in rats of
either sex, when nicotine was applied over 26 weeks following birth. There was a gender-specific imbalance in
rats which received the carcinogen only, in favour of a lower tumour yield in females (P<0.04), which
became less apparent when nicotine was given additionally. These findings suggest that nicotine is capable of
modulating the expression of chemically induced tumours of the neurogenic system in a favourable way.
Numerous epidemiologic and clinical studies indicate a high
correlation between smoking and various types of cancer. To
date, the causative factors of neoplasms associated with
smoking habits have not been identified with certainty.
Tobacco smoke itself is a very complex mixture containing a
variety of different classes of carcinogens such as
nitrosamines (Druckrey & Preussmann, 1962) or polycyclic
aromatic hydrocarbons (Yanysheva & Antonomov, 1976).
The importance of the respective single agents in tobacco
smoke in the mechanisms of tumour development is the field
of current research. To avoid a multitude of concurrent
mechanisms that are active in tobacco smoke, it seems
necessary to investigate at first the effects of purified
compounds in order to identify their inherent risk precisely.
Since nicotine is the main attraction when consuming
cigarettes, this constituent was primarily tested for a possible
carcinogenic action. The majority of these studies revealed
that neither nicotine nor its primary metabolites were
carcinogenic (LaVoie et al., 1985; Martin et al., 1979;
Schmahl & Osswald, 1968; Toth, 1982), although two studies
indicated a weak tumorigenic action (Boyland, 1968;
Truhaut et al., 1984). Furthermore, a limited number of
studies were concerned with a possible modulation of
carcinogenesis by nicotine (Bock, 1980; Gurkalo & Volfson,
1982; Habs & Schmahl, 1976, 1984; Ito et al., 1984; LaVoie
et al., 1985). These authors used well-established chemically-
induced models for the detection of nicotine-related changes
in tumour expression. Since no uniform answer was obtained
from these studies, the question remains whether certain
types of cancer can be influenced specifically by nicotine
(Bock, 1980; Gurkalo & Volfson, 1982; LaVoie et al., 1985)
and whether especially sensitive periods of life exist such as
the perinatal period, in which even a very low dose of this
agent can lead to tumour development. The latter
assumption could be relevant, since a remarkable number of
women do not change their smoking habits during
pregnancy and subsequent lactation period. This is the case,
even though the influence of nicotine on the progeny has
been established in terms of underweight births in animals as
well as man (Becker et al., 1968; Becker & Martin, 1971;
Martin et al., 1979). Consequently, the present experiments
were designed to investigate the possible influence of
perinatal nicotine administration on transplacental
carcinogenesis in Sprague Dawley rats by N-methylnitrosourea
(MNU).
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Materials and methods
Chemicals
Commercially available nicotine tartrate was obtained from
Serva (Heidelberg, FRG). MNU was synthesized by Dr M.
Wiessler (Institute of Toxicology and Chemotherapy,
German Cancer Research Center, Heidelberg, FRG). Both
compounds were dissolved in water at 0.4% and 1%,
respectively; fresh solutions were prepared before each
administration.
Animals and tumour induction
Sixty male and 120 female Sprague Dawley rats were
supplied at age 20+2 weeks by the Zentralinstitut fur
Versuchstierzucht (Hannover, FRG). They were kept
thereafter under conventional conditions (2 animals per
Macrolon III cage, 22 +2 C, relative humidity: 55 +5%,
dark-light rhythm: 12h) and received Altromin pellets (diet
1320) and tap water ad libitum. As a precondition of
transplacental induction one male and two females of this
parent generation were matched for 3 days. Onset of
gravidity was assumed, once spermatic filaments were micro-
scopically detected; this day was counted as day 1 of the
gestational period (day I post coitum, p.c.). Pregnant
animals were randomly distributed to experimental groups
(Table I). Dams of groups 1, II and IV received 30mg MNU
kg-1 body wt by gavage (Acufirm 1.5 x 82mm) on day
20p.c. Nicotine (0.4mgkg-1) was administered s.c. to dams
daily either before (days 14-20p.c., groups II and III,
respectively) or after birth (days 1-20 post partum, groups
IV and V, respectively). The offspring of the latter two
groups additionally received injections of nicotine tartrate
twice weekly over 22 weeks starting at week 4 of life.
Animals of group VI served as untreated control. During the
experiment all animals were inspected twice daily. Rats at an
advanced stage of tumour growth were killed prior to their
natural death. Dead animals were carefully dissected with
special emphasis given to the central nervous system and
peripheral nerves. For each animal the actual cause of death
was recorded. The neurogenic tissue, all tumours and organs
showing macroscopical changes were fixed in a 7% formalin
solution for histologic evaluation. The malignancy of the
individual tumours was assessed by histological grading and
by their potential to cause a life-threatening local expansion;
consequently all neurogenic tumours with the exception of
tumours of the pituitary gland were subsumed to be
malignant tumours.
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Table I Experimental design
Nicotine s.c.b
MNU p.o.a
Days Weeks Median
Number of Dose Days Dose Days p p d p p d Mortalityg survival
F,-animals (mgkg- ) p.c.C (mgkg 1) p.c.c (dam) (oJjspring) % time (range)h
Group 1 30 3 97 267
30 20 (150-387)
30 Y 80 246
(154-448)
Group II 31 3 80 270
30 20 0.4 1420e (111-452)
29 Y 79 274
(149-443)
Group III 30 3 0
0.4 14-20e
30 $ 7 350
(276-423)
Group IV 31 3 77 316
30 20 0.4 1-200 4-26' (169-430)
29 Y 76 296
(79-419)
Group V 303 0
0.4 1-200 4-26(
30 + 10 423
(384-443)
Group VI 30 0
Control
30 Y 3 328
aN-methylnitrosourea administered p.o. to dams. bNicotine tartrate administered s.c. cPost coitum (administered to dam). dPost
partum. 'Daily administration. '2 administrations per week. o,, mortality before termination of the experiment due to occurrence of
MNU-induced tumours. hMedian survival times of animals that died before termination of experiment.
Statistical evaluation
Incidences of organ-specific malignancies were analyzed by
comparison of age-adjusted observed versus expected
numbers of affected animals according to Peto et al. (1980).
Results
No influence of the treatment on either duration of
pregnancy (21 days +2 days) or the average number of
surviving descendants per litter (13 + 1) was seen. In
comparison with the groups not receiving MNU (groups III,
V? VI; Figure 1) transplacental administration of 30mgkg-1
MNU (group I, II, IV) significantly decreased the body wt
gain in both males and females. Injections of nicotine did
not affect this parameter and neither did they cause
symptoms of acute or subacute toxicity. The long-term
toxicologic effect of MNU administration resulted in an
overall malignancy rate of 85% (Group I, Table II). These
tumours were mainly of neurogenic origin (62% incidence in
the F,-generation), additionally 3% of the progeny showed
tumours of the kidney and 30% of the females had tumours
of the mammary gland. Histologically, 85% of the
neurogenic tumours were found to be sarcomas, located in
the peritoneal cavity or associated with the spinal cord. The
remaining tumours of the nervous system proved to be
gliomas (7%) and neurinomas (7%) in type. The gender-
specific subdivision of MNU-treated animals presented a
similar overall tumour incidence. Significant differences,
however, were observed with regard to the occurrence of the
two main tumour types: 30% less females presented with
neurogenic tumours (P<0.04; compared to males) and the
females experienced mammary lesions (P<0.01) in contrast
to the males.
At termination of the experiment, 97% of the males and
80% of the females had died of MNU-induced tumours.
Administration of nicotine before (Group II) or following
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Figure 1 Mean body weight gain in female (A) and male (B)
SD-rats following transplacental induction with MNU (groups I
, II* *, IV C] L) in relation to nicotine-treated
(groups III A A, V 0 O) and -untreated controls
(group VI *-----0).
(Group IV) birth resulted in a reduction of the overall load
of malignant tumours to 68% and 63% (P=0.08 and
0.0015), respectively. This was due to a decrease in the
number of malignancies of the nervous system and of the
mammary gland. The occurrence of neurogenic tumours was
reduced more when nicotine was administered over a period
of 26 weeks following birth (Group IV vs. Group I;
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Table II Distribution of benign and malignant tumours
Number ofanimals with Origin ofbenign tumours, (%) Origin of malignant tumours, (%)
Benign Malignant Nervous Mammary Other Nervousa Mammary
tumours (N) tumours (N) system gland sites systemaa gland Kidney
Group I 3 7 (23) 26 (87) ( ) - ) 7 (23) 23 (77) - ) 1 (3)
V2 5 (17) 25 (83) (-) 2 (7) 3 (10) 14 (47) 9 (30) 1 (3)
Group II 3 7 (23) 21 (68) 1 (3) 1 (3) 5 (16) 16 (52)c () 1 (3)
7 (24) 20 (69) () 3 (10) 4 (14) 14 (48)d 3 (10)
Group III 4 - - - - - - - -
¶' 1 (3) 2 (7) 1 (3) () () () 2 (7) ()
Group IV 3 3 (10) 22 (71) ( ) ( ) 3 (10) 18 (58)b.e ) 1 (3)
14 (48) 16 (55) 1 (3) 6 (20) 7 (24) 10 (34)bd 1 (3) 2 (7)
Group V () () () () ()- (-) () ()
W) 2 (7) 1 (3) 1 (3) 1 (3) -() --) 1 (3) -()
Group VI () 1 (3) () () () (3) -() ()
2 (7) -()--) 2 (7) -() -() -() -()
Malignant tumours of low incidence (No.).
Group I: Odontoblastoma of the lower jaw (1), adenocarcinoma of the lung (1), squamous cell carcinoma of the cutis
(1).
Group 11: Fibrosarcoma of the cutis (2), adenocarcinoma of the thyroid gland (1), squamous cell carcinoma of the lower
jaw (1), odontoblastoma of the lower jaw (1), osteosarcoma (1), leiomyosarcoma of the uterus (1).
Group IV: Transitional cell carcinoma of the urinary tract (2), adenocarcinoma of the external auditory canal (2),
adcnocarcinoma of the prostata (1), squamous cell carcinoma of the lower jaw (1), fibrosacroma of the
peritoneal cavity (1).
'Neurogenic sarcomas, astrocytomas, oligodendroblastomas, microgliomas and neurinomas of the n. trigeminus were
subsumed to be malignant tumours of the nervous system. aaIn group I four, in group II one and in group IV three animals
had 2 neurogenic tumours. bSignificantly different from group I; P=0.0015. cSignificantly different from males of group I;
P=0.035. dFemales of groups I, 11, IV significantly different from males of groups I, II and IV; P=0.044. eSignificantly
different from males of group I; P=0.0008. 'Significantly different from males of group 1; P=0.04.
P=0.0015) compared to the transplacental administration of
nicotine (Group IV vs. Group II; P=0.08). Concomitant
with the decreased occurrence of neurogenic tumours in rats
treated with nicotine following birth, a shift in tumour type
was observed from neurogenic sarcomas (70% instead of
85%) to gliomas (27% instead of 7%) compared with
MNU-treated controls. Interestingly, the gender-specific
imbalance in the occurrence of neurogenic tumours following
MNU was diminished to an insignificant difference of 4%
(P=0.4) in group II and of 14% (P=0.25) in group IV. The
differences found in tumours of the mammary gland,
however, were not significant according to an age-adjusted
analysis of observed versus expected numbers of affected
animals, although considerably less malignant mammary
tumours appeared in both MNU and nicotine treated
groups.
The regular injection of nicotine alone (groups III and V,
respectively) had no overt influence on the survival or
tumour yield in comparison to untreated controls.
Discussion
The directly acting carcinogen MNU is well known to
induce a variety of tumours, depending on the time and
route of administration (Berger & Schmahl, 1986; IARC
Monographs, 1978). In a first study on the modulation of
MNU-induced tumorigenesis by nicotine in sexually
premature rats, no apparent differences were obtained in the
development of mammary tumours (Habs & Schmahl, 1984).
This study was designed to assess the influence of nicotine
on the same carcinogen during the perinatal stages of life.
No influence on tumour development was exerted by
nicotine alone (groups III and V versus group IV); this
finding is in accordance with previously published data
(Martin et al., 1979). In comparison to a study by
Alexandrov (1976), a higher dose level of MNU (30mgkg-1
instead of 20 mgkg-1) and a different route of
administration (p.o. instead of i.p.) were used. This resulted
in a 20% increased yield of neurogenic tumours and the
latency period was shortened by 250 days. The potential of
MNU, however, in inducing neurogenic tumours was
distinctly lower than that of ENU in parallel experiments
(Habs & Schmahl, 1976; Ivankovic & Druckrey, 1968). At
the same dose (mg kg-1 bodywt) ENU caused an incidence
of neurogenic tumours of 92% in males and 90% in females.
A gender-specific imbalance of neurogenic tumours was
observed only at a dose of 10mgkg-1 ENU (62% incidence
in males and 50% incidence in females), which was
comparable to the results obtained in the present experiment.
In contrast to this study, however, lifelong administration of
nicotine (i.p.) resulted in 12% less neurogenic tumours in
males, but in 16% more neurogenic tumours in females.
Thus, nicotine did not significantly modulate the
carcinogenic potential of ENU following transplacental
administration.
Similar to that study, no change in the yield of urinary
bladder tumours was obtained when nicotine was adminis-
tered to N-butyl-N-(4-hydroxybutyl) nitrosamine-induced
male F344 rats (Ito et al., 1984). Unlike this result a signifi-
cant enhancement in the number of N-methyl-N-nitro-N-
nitroso-guanidine-induced tumours of the glandular stomach
was detected in male albino rats following coadministration
of nicotine (Gurkalo & Volfson, 1982). Another experiment
which concentrated on the modification of N-(4-(5-nitro-
2-furyl)-2-thiazolyl)formamide-induced tumours following
administration of nicotine-derived metabolic products in male
F344 rats, reported an increased total tumour load of rats,
when these compounds were coadministered (LaVoie et al.,
1985). Interestingly, the incidence of urinary bladder tumours
was significantly reduced. This is the only report which
details an inhibitory effect of nicotine-related compounds on
tumorigenesis, at least in one tissue. The results of the present
study are even more surprising, since no complementary
increase to the reduced occurrence of neurogenic tumours
was detected in other tissues.
So far, no sufficient explanation is available for this
inhibitory effect of nicotine on the development of40 M.R. BERGER et al.
neurogenic tumours. It might be speculated that the release
of catecholamines caused by the administration of the
neurotropic nicotine (Arqueros et al., 1978) resulted in
specific mechanisms of action leading to growth inhibition of
neoplasms of the ncurogenic tissue. In view of the reduced
gender-specific differences in the observed tumour load
following MNU and nicotine, the assumption of a hormonal
influencc cannot be excluded. A direct influence of nicotine
on the decomposition or pharmacokinetics of MNU can be
excluded, however, at least in group IV, where the
administration of the modulating agent started one day after
injection of the carcinogen. It is furthermore interesting to
note that the seemingly protective effect of nicotine was
observed independently of the fact, whether nicotine was
administered before or after birth of the animals. The
results, of course, do not mean that nicotine should be
regarded as a beneficial or even harmless agent, since all
other studies (Gurkalo & Volfson, 1982; Habs & Schmahl,
1984; Ito et' al., 1984; LaVoie et al., 1985), including one on
the same type of tissue (Habs & Schmahl, 1976), indicated
an increased carcinogenic expression following this alkaloid
or at least showed no apparent influence on experimental
tumorigenesis. The observed unexpected modulation of
carcinogenesis, however, warrants further investigations on
compounds structurally related to MNU, such as alkylating
cytotoxic agents.
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